| Dr Gregory Balabanian, MD | |
|
200 Medical Center Dr, Hazard, KY 41701-9466 | |
| (606) 487-7510 | |
| (606) 439-6793 |
| Full Name | Dr Gregory Balabanian |
|---|---|
| Gender | Male |
| Speciality | Infectious Disease |
| Experience | 13 Years |
| Location | 200 Medical Center Dr, Hazard, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033406277 | NPI | - | NPPES |
| 7100528170 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 51067 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hazard Arh Regional Medical Center | Hazard, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Appalachian Regional Healthcare Inc. | 0840107835 | 232 |
News Archive
City of Hope researchers received approval from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive type of brain tumor. Karen S. Aboody, M.D., associate professor in City of Hope's Department of Neurosciences, leads the research team that developed this treatment strategy. Jana Portnow, M.D., assistant professor and assistant director of the Brain Tumor Program at City of Hope, is the principal investigator for the clinical trial.
Hospitals and healthcare systems worldwide are overwhelmed, with many facilities full of patients requiring emergency care for coronavirus disease (COVID-19) that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 disease causes severe respiratory illness in patients, with some needing mechanical ventilation.
About half of smokers seeking treatment for smoking cessation have a history of depression. Compared with smokers who are not depressed, those who suffer from a major depressive disorder have greater difficulty quitting.
Autism produces a widespread range of antibodies that act against brain tissue and one protein in particular seems to be the major target of these antibodies claim a group of scientists in the July issue of the Journal of Neuroimmunology.
BioMed Realty Trust, Inc. today announced the signing of a new lease at its 301 Binney Street laboratory research facility in Cambridge, Massachusetts. The world-renowned Broad Institute of MIT and Harvard agreed to a ten-year lease for approximately 80,000 square feet in the heart of Cambridge's biotechnology super-cluster.
› Verified 5 days ago
| Entity Name | Appalachian Regional Healthcare Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528148012 PECOS PAC ID: 0840107835 Enrollment ID: O20031125000520 |
News Archive
City of Hope researchers received approval from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive type of brain tumor. Karen S. Aboody, M.D., associate professor in City of Hope's Department of Neurosciences, leads the research team that developed this treatment strategy. Jana Portnow, M.D., assistant professor and assistant director of the Brain Tumor Program at City of Hope, is the principal investigator for the clinical trial.
Hospitals and healthcare systems worldwide are overwhelmed, with many facilities full of patients requiring emergency care for coronavirus disease (COVID-19) that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 disease causes severe respiratory illness in patients, with some needing mechanical ventilation.
About half of smokers seeking treatment for smoking cessation have a history of depression. Compared with smokers who are not depressed, those who suffer from a major depressive disorder have greater difficulty quitting.
Autism produces a widespread range of antibodies that act against brain tissue and one protein in particular seems to be the major target of these antibodies claim a group of scientists in the July issue of the Journal of Neuroimmunology.
BioMed Realty Trust, Inc. today announced the signing of a new lease at its 301 Binney Street laboratory research facility in Cambridge, Massachusetts. The world-renowned Broad Institute of MIT and Harvard agreed to a ten-year lease for approximately 80,000 square feet in the heart of Cambridge's biotechnology super-cluster.
› Verified 5 days ago
| Entity Name | Arh Tug Valley Health Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639949696 PECOS PAC ID: 4183953805 Enrollment ID: O20190905002344 |
News Archive
City of Hope researchers received approval from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive type of brain tumor. Karen S. Aboody, M.D., associate professor in City of Hope's Department of Neurosciences, leads the research team that developed this treatment strategy. Jana Portnow, M.D., assistant professor and assistant director of the Brain Tumor Program at City of Hope, is the principal investigator for the clinical trial.
Hospitals and healthcare systems worldwide are overwhelmed, with many facilities full of patients requiring emergency care for coronavirus disease (COVID-19) that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 disease causes severe respiratory illness in patients, with some needing mechanical ventilation.
About half of smokers seeking treatment for smoking cessation have a history of depression. Compared with smokers who are not depressed, those who suffer from a major depressive disorder have greater difficulty quitting.
Autism produces a widespread range of antibodies that act against brain tissue and one protein in particular seems to be the major target of these antibodies claim a group of scientists in the July issue of the Journal of Neuroimmunology.
BioMed Realty Trust, Inc. today announced the signing of a new lease at its 301 Binney Street laboratory research facility in Cambridge, Massachusetts. The world-renowned Broad Institute of MIT and Harvard agreed to a ten-year lease for approximately 80,000 square feet in the heart of Cambridge's biotechnology super-cluster.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gregory Balabanian, MD 200 Medical Center Dr, Hazard, KY 41701-9466 Ph: (606) 487-7510 | Dr Gregory Balabanian, MD 200 Medical Center Dr, Hazard, KY 41701-9466 Ph: (606) 487-7510 |
News Archive
City of Hope researchers received approval from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive type of brain tumor. Karen S. Aboody, M.D., associate professor in City of Hope's Department of Neurosciences, leads the research team that developed this treatment strategy. Jana Portnow, M.D., assistant professor and assistant director of the Brain Tumor Program at City of Hope, is the principal investigator for the clinical trial.
Hospitals and healthcare systems worldwide are overwhelmed, with many facilities full of patients requiring emergency care for coronavirus disease (COVID-19) that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 disease causes severe respiratory illness in patients, with some needing mechanical ventilation.
About half of smokers seeking treatment for smoking cessation have a history of depression. Compared with smokers who are not depressed, those who suffer from a major depressive disorder have greater difficulty quitting.
Autism produces a widespread range of antibodies that act against brain tissue and one protein in particular seems to be the major target of these antibodies claim a group of scientists in the July issue of the Journal of Neuroimmunology.
BioMed Realty Trust, Inc. today announced the signing of a new lease at its 301 Binney Street laboratory research facility in Cambridge, Massachusetts. The world-renowned Broad Institute of MIT and Harvard agreed to a ten-year lease for approximately 80,000 square feet in the heart of Cambridge's biotechnology super-cluster.
› Verified 5 days ago
Dr. Raymond Elsoueidi, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Medical Center Dr, Hazard, KY 41701 Phone: 606-439-6600 | |
Dr. Thomas E. Karelis Jr., MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 311 Roy Campbell Dr, Hazard, KY 41701 Phone: 606-487-0776 Fax: 606-487-0777 | |
Vidya B Yalamanchi, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Medical Center Dr, Hazard, KY 41701 Phone: 606-487-7510 Fax: 606-439-6793 | |
Dr. Jeffery Prater, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 271 E Main St, Hazard, KY 41701 Phone: 606-439-1316 Fax: 606-439-3922 | |
Dr. Samuel Dean Bailey, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Medical Center Dr, Hazard, KY 41701 Phone: 606-487-7902 | |
Mr. Ionut Stefanescu Sturz, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 311 Roy Campbell Drive, Hazard, KY 41701 Phone: 606-487-0776 Fax: 606-487-0777 |